Podcasts about ivacaftor

CHEST April 2024, Volume 165, Issue 4 Sonia Graziano, PsyD, joins CHEST Podcast Moderator Gretchen Winter, MD, to discuss how elexacaftor/tezacaftor/ivacaftor affects mental health, cognitive processing, neuropsychological side effects, GI symptoms, and health-related quality of life in people with cystic fibrosis. DOI: https://doi.org/10.1016/j.chest.2023.10.043   Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.

Check out this milestone episode as we return to Cystic Fibrosis from a more pediatric perspective! Don't sweat it as Dr. Ina St. Onge returns to walk us through newborn screening,  early clinic visits, and the nuances of CFTR modulator therapy. 

Durante a centésima quinta reunião da Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde, Conitec, foi feita a apreciação inicial do medicamento tezacaftor/ivacaftor, com nome comercial Symdeko. Infelizmente, a Conitec recomendou para a consulta pública com parecer preliminar desfavorável à incorporação no SUS. Com essa decisão e a abertura da consulta pública no site da Comissão, chegou a hora de toda a comunidade da fibrose cística se unir para tentar reverter essa situação. Neste podcast, compartilhamos informações importantes sobre como participar da consulta pública nº 05 referente ao Symdeko até o dia 04/04/2022. Para mais informações, acesse https://contribuacomfc.unidospelavida.org.br/. Roteiro: Kamila Vintureli e Gabriel Johnson Locução e edição: Kamila Vintureli Trilha: Felipe Caldo

The recent development of triple CFTR modulation means that up to 90% of people with CF will be eligible for ‘highly effective’ CFTR modulator therapy. In this podcast, Rachael Moses, Multimedia Editor of Thorax, and Dr Peter Barry, Consultant Respiratory Physician, Manchester Adult Cystic Fibrosis Centre, discuss the long-term adherence to and effects of ivacaftor on lung function, weight and healthcare utilisation in people with cystic fibrosis and the Gly551Asp mutation. Read the related paper: https://thorax.bmj.com/content/early/2021/03/24/thoraxjnl-2020-215556

This episode of Drug Cards Daily is on the drug Trikafta. As of 2020 it is Brand only. Trikafta consists of three drugs which are elexacaftor, ivacaftor, tezacaftor. It is twice a day dosing with 2 tablets in the morning and 1 tablet (12 hours later) in the evening. The morning tablet is orange in color and consists of elexacaftor 100 mg + tezacaftor 50mg + ivacaftor 75 mg while the evening dose (which is a light blue colored tablet) consists of ivacaftor 150 mg. Currently the drug is approved for use in ages 12 years and older. The main concerns are patients must have the F508del mutation in the CFTR gene have healthy liver function. Patients without the F508del mutation will not benefit from this drug. The other concern is that CYP3A inducers and inhibitors affect this drug greatly so that should always be considered when starting a patient on this treatment. Go to DrugCardsDaily.com for episode show notes which consist of the drug summary, quiz, and link to the drug card for FREE! Please SUBSCRIBE, FOLLOW, and RATE on Spotify, Apple Podcasts, or wherever your favorite place to listen to podcasts are. The main goal is to go over the Top 200 Drugs with the occasional drug of interest. Also, if you'd like to say hello, suggest a drug, or leave some feedback I'd really appreciate hearing from you! Leave a voice message at anchor.fm/drugcardsdaily or find me on twitter @drugcardsdaily --- Send in a voice message: https://anchor.fm/drugcardsdaily/message

As consultas públicas referentes aos medicamentos Kalydeco (ivacaftor) e Orkambi (lumacaftor/ivacaftor) já estão disponíveis e o Unidos pela Vida - Instituto Brasileiro de Atenção à Fibrose Cística, traz neste episódio informações importantes sobre como participar. Roteiro: Kamila Vintureli e Verônica Stasiak Bednarczuk de Oliveira Locução: Kamila Vintureli Data de gravação: 12 de agosto de 2020

Drug discovery is a complicated and expensive process that can take years for a drug to finally come to market. In this week's podcast we walk you through the process of drug discovery looking through the lens of cystic fibrosis. We explain the many steps including screens for different drug compounds, the different phases of testing and the vast regulations that drugs in the US are under to protect people! Finally, we link this back to COVID-19 and some of the drugs that are currently being tested to see if they help treat COVID-19 symptoms. // SOURCES:SourcesCystic Fibrosis: https://www.cff.org/aCystic Fibrosis: https://www.cff.org/Research/About-Our-Research/Research-Milestones/Cystic Fibrosis: https://ghr.nlm.nih.gov/gene/CFTR#:~:text=Normal%20Function,%2C%20tears%2C%20and%20digestive%20enzymes.Ivacaftor discovery: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770629/pdf/dddt-7-929.pdfOriginal Ivacaftor screen: https://pubmed.ncbi.nlm.nih.gov/16443646/Ivacaftor company: https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecotm-ivacaftor-first-medicine-treatIvacaftor clinical trials: https://www.clinicaltrialsarena.com/projects/ivacaftor-treatment-for-cystic-fibrosis/Follow-up characterization: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773991/Drug discovery process: https://www.ncbi.nlm.nih.gov/books/NBK22930/Drug discovery process http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdfDrug discovery process: https://www.fda.gov/drugs/development-approval-process-drugsDrug failure/approval: https://blogs.sciencemag.org/pipeline/archives/2019/05/09/the-latest-on-drug-failure-and-approval-ratesCOVID-19 Treatments: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/chloroquine-or-hydroxychloroquine/COVID-19 Treatments: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatmentRight to Try: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-tryHydroxychloroquine shortage: https://www.arthritis.org/drug-guide/medication-topics/plaquenil-shortageHydroxychloroquine shortage: https://www.lupus.org/news/fda-recognizes-hydroxychloroquine-and-chloroquine-shortages

In this episode, guest host Dr. David Poetker speaks with Dr. Brad Woodworth and Dr. Do-Yeon. They will discuss the article: In‐vitro evaluation of a ciprofloxacin‐ and ivacaftor‐coated sinus stent against Pseudomonas aeruginosa biofilms. Read the article in International Forum of Allergy and Rhinology Listen and subscribe for free on Apple Podcasts , Google Play […]

Nutritional Issues in Cystic Fibrosis

Benefits of CFTR Modification Beyond FEV1 Improvement

The Effects of CFTR-modifying Therapies

Originally presented at the 2013 North American Cystic Fibrosis Conference, this program covers differentiation of CF classes and current/potential therapies and using the CFTR2 database.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.